NASDAQ$TNGX
Tango Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Tango Therapeutics Inc reported Q2 2025 financial results showing continued net losses amid ongoing R&D activities.
For the three months ended June 30, 2025, the company recognized $3.2 million in collaboration revenue. Operating expenses totaled $44.1 million, resulting in a net loss of $38.9 million or $0.35 per share. Cash and cash equivalents stood at $39.3 million at quarter end.
- Q2 2025 collaboration revenue was $3.2 million, down from $19.9 million in Q2 2024 due to lower research activities under the Gilead agreement.
- Research and development expenses decreased to $32.8 million from $38.7 million year-over-year.
- Net loss widened to $38.9 million compared to $25.6 million in the prior-year quarter.
- Cash position declined to $39.3 million as the company continued funding its precision oncology pipeline.
Headline financials
Revenue & EPS history
Tango Therapeutics · Revenue · Quarterly
$3.18M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+0.6%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+25.8%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+36.4%
Q4 2025
Best reaction
-45.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +8.6% | -12.1% | +31.7% | |
| Q4 2025 | +36.4% | +33.6% | +75.1% | |
| Q3 2025 | +0.2% | -1.7% | +23.6% | |
| Q1 2025 | +17.1% | +31.6% | +315.8% | |
| Q4 2024 | -6.5% | -21.0% | -36.9% | |
| Q3 2024 | -45.4% | -34.7% | -34.7% | |
| Q2 2024 | -1.8% | -5.7% | +20.9% | |
| Q1 2024 | -0.8% | -6.9% | -12.1% | |
| Q4 2023 | -9.7% | -14.4% | -17.4% | |
| Q3 2023 | +3.8% | -12.1% | +6.6% | |
| Q2 2023 | +1.2% | +120.9% | +113.5% | |
| Q1 2023 | +6.4% | +4.4% | -0.3% | |
| Q4 2022 | -9.4% | -5.3% | -21.6% | |
| Q3 2022 | -5.3% | +6.7% | -1.3% | |
| Q2 2022 | +22.4% | +32.8% | -8.1% | |
| Q1 2022 | -7.6% | +1.2% | -3.8% | |
| Q4 2021 | +0.3% | +6.8% | +1.3% | |
| Q3 2021 | +0.4% | +5.2% | -10.7% | |
| Q2 2021 | +1.1% | -2.2% | +49.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro